Mizuho analyst Joseph Catanzaro lowered the firm’s price target on Revolution Medicines (RVMD) to $140 from $143 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines price target raised to $120 from $75 at Piper Sandler
- Revolution Medicines price target raised to $115 from $109 at BofA
- Revolution Medicines price target raised to $144 from $100 at Wells Fargo
- Revolution Medicines: Advancing RAS Inhibitor Pipeline and Strong Cash Runway Support Buy Rating
- Revolution Medicines reports Q4 EPS ($1.86), consensus ($1.56)